1. Tau PET and relative cerebral blood flow in dementia with Lewy bodies: A PET study
- Author
-
Frederik Barkhof, Albert D. Windhorst, Emma M. Coomans, Afina W. Lemstra, Sander C.J. Verfaillie, Ph. Scheltens, Ronald Boellaard, W.M. van der Flier, Sandeep S.V. Golla, Hayel Tuncel, Tessa Timmers, Emma E. Wolters, B.N.M. van Berckel, M. van de Beek, Denise Visser, Rik Ossenkoppele, Radiology and nuclear medicine, Amsterdam Neuroscience - Neurodegeneration, Neurology, APH - Personalized Medicine, and APH - Methodology
- Subjects
Lewy Body Disease ,medicine.medical_specialty ,Neurology ,Cognitive Neuroscience ,Relative cerebral blood flow ,Dementia with Lewy bodies ,tau Proteins ,lcsh:Computer applications to medicine. Medical informatics ,behavioral disciplines and activities ,050105 experimental psychology ,lcsh:RC346-429 ,03 medical and health sciences ,0302 clinical medicine ,Cerebrospinal fluid ,Cognition ,Alzheimer Disease ,Internal medicine ,mental disorders ,medicine ,Memory span ,Humans ,0501 psychology and cognitive sciences ,Radiology, Nuclear Medicine and imaging ,Cognitive Dysfunction ,lcsh:Neurology. Diseases of the nervous system ,business.industry ,05 social sciences ,Parietal lobe ,Neuropsychology ,Binding potential ,Regular Article ,medicine.disease ,nervous system diseases ,Cerebral blood flow ,nervous system ,Cerebrovascular Circulation ,Positron-Emission Tomography ,Cardiology ,FDG PET ,lcsh:R858-859.7 ,Neurology (clinical) ,Tau ,business ,030217 neurology & neurosurgery ,circulatory and respiratory physiology - Abstract
Highlights • The amount of tau binding in DLB was minimal and did not differ from controls. • Relative cerebral blood flow (rCBF), but not tau PET, was related to cognitive impairment. • rCBF is more strongly related to clinical characteristics in DLB than tau PET., Purpose Alpha-synuclein often co-occurs with Alzheimer’s disease (AD) pathology in Dementia with Lewy Bodies (DLB). From a dynamic [18F]flortaucipir PET scan we derived measures of both tau binding and relative cerebral blood flow (rCBF). We tested whether regional tau binding or rCBF differed between DLB patients and AD patients and controls and examined their association with clinical characteristics of DLB. Methods Eighteen patients with probable DLB, 65 AD patients and 50 controls underwent a dynamic 130-minute [18F]flortaucipir PET scan. DLB patients with positive biomarkers for AD based on cerebrospinal fluid or amyloid PET were considered as DLB with AD pathology (DLB-AD+). Receptor parametric mapping (cerebellar gray matter reference region) was used to extract regional binding potential (BPND) and R1, reflecting (AD-specific) tau pathology and rCBF, respectively. First, we performed regional comparisons of [18F]flortaucipir BPND and R1 between diagnostic groups. In DLB patients only, we performed regression analyses between regional [18F]flortaucipir BPND, R1 and performance on ten neuropsychological tests. Results Regional [18F]flortaucipir BPND in DLB was comparable with tau binding in controls (p > 0.05). Subtle higher tau binding was observed in DLB-AD+ compared to DLB-AD- in the medial temporal and parietal lobe (both p
- Published
- 2020
- Full Text
- View/download PDF